Menu
Not yet recruiting NCT05577078

TriBEL Registry: National Belgian Registry of Percutaneous Tricuspid Valve Repair Using a Transcatheter Edge-to-edge Repair Technique

Observational Tricuspid Valve Regurgitation

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Transcatheter edge-to-edge repair (TEER).
Who it may be relevant to
Registry conditions: Tricuspid Valve Regurgitation. Basic parameters: 18 years — 110 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

In this study, patients who have undergone or will undergo a transcatheter edge-to-edge repair (TEER) for tricuspid valve regurgitation (TR) will be followed up for 5 years. The goal of this prospective and retrospective, observational, non-randomized, multicenter registry is to confirm that TEER is a feasible, safe and effective treatment option for TR and to evaluate the long-term efficacy and safety of TEER. The main endpoints are: * Change in tricuspid regurgitation grade: number of patients with a reduction in tricuspid regurgitation score by at least one grade * Composite of major adverse event: number of patients with composite of major adverse event (cardiovascular mortality, acute kidney injury, myocardial infarction, stroke or TIA, coronary revascularization, new onset AF or ventricular arrhythmia)

Interventions

  • Procedure Transcatheter edge-to-edge repair (TEER)
    Minimally invasive transcatheter-based edge-to-edge repair technique for tricuspid regurgitation

Primary outcome measures

  • Number of patients with a reduction in tricuspid regurgitation score by at least one grade [Time frame: 30 days]
  • Composite of major adverse event [Time frame: 1 year]
Secondary outcome measures (8)
  • Number of patients with a reduction in tricuspid regurgitation score by at least one grade at 6 months post-procedure [Time frame: 6 months]
  • Number of patients with a reduction in tricuspid regurgitation score by at least one grade 1 year post-procedure [Time frame: 1 year]
  • Number of patients with a reduction in tricuspid regurgitation score by at least one grade 2 years post-procedure [Time frame: 2 years]
  • Number of patients with a reduction in tricuspid regurgitation score by at least one grade 3 years post-procedure [Time frame: 3 years]
  • Number of patients with a reduction in tricuspid regurgitation score by at least one grade 4 years post-procedure [Time frame: 4 years]
  • Number of patients with a reduction in tricuspid regurgitation score by at least one grade 5 years post-procedure [Time frame: 5 years]
  • Composite of major adverse event at discharge [Time frame: 5 days]
  • Composite of major adverse event at 5 years post-procedure [Time frame: 5 years]

Eligibility criteria

Inclusion criteria

  • At least 18 years old
  • Eligible for TEER procedure
  • Informed consent signed

Exclusion criteria

  • Unwilling to provide informed consent

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT05577078 · TriBEL

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗